What is iLoF?
iLoF is at the forefront of digital health, developing an innovative AI platform designed to revolutionize personalized drug discovery and development. The company's cloud-based library leverages unique optical fingerprint technology and artificial intelligence to enable non-invasive patient tracking, screening, and stratification, specifically tailored to the rigorous requirements of clinical trials. This advanced approach promises substantial cost savings and accelerated timelines, while simultaneously ensuring a more qualified participant pool for crucial research. iLoF's technology is being applied across a spectrum of critical diseases, including Alzheimer's, COVID-19, and ovarian cancer, with the ultimate goal of significantly improving treatment outcomes.
How much funding has iLoF raised?
iLoF has raised a total of $6.5M across 2 funding rounds:
Angel/Seed
$5M
Other Financing Round
$1.5M
Angel/Seed (2022): $5M with participation from M12, Quiet Capital, and Faber SpA
Other Financing Round (2024): $1.5M, investors not publicly disclosed
Key Investors in iLoF
M12
M12, Microsoft's Venture Fund, is a key investor specializing in enterprise software and applied AI, providing strategic go-to-market resources to its portfolio companies.
Quiet Capital
Quiet Capital is a founder-led venture capital firm that backs ambitious technology entrepreneurs, offering patient capital and a collaborative network across various markets including health.
Faber SpA
Faber SpA, an industrial group with a global presence, brings a unique perspective, potentially focusing on the operational and manufacturing aspects of scaling technology companies.
What's next for iLoF?
With the recent influx of major strategic investment, iLoF is poised for accelerated scaling and further development of its AI-powered drug discovery platform. This latest round of financing, following earlier seed-stage capital, indicates a transition towards later-stage growth and market penetration. The company is expected to enhance its technological capabilities, expand its disease research focus, and forge deeper partnerships within the pharmaceutical and biotechnology sectors. The strategic backing suggests a clear path towards commercialization and broader adoption of its innovative solutions for clinical trial optimization and personalized medicine.
See full iLoF company page
